The State of Restricted-Vertical Vendor Trust 2026

Buyers are flooding into peptides, SARMs, research chemicals and gray-market GLP-1s at the exact moment the channel is most rigged against them. A fully-sourced look at the enforcement crackdown, the fake-COA crisis, real scam rates, and exploding demand — and why an un-bribable trust layer is the missing infrastructure.

Executive Summary The market for restricted-vertical products — peptides, SARMs, research chemicals, kratom, nootropics, and gray-market GLP-1 weight-loss drugs — is growing faster than almost any corner of e-commerce. In 2026 it is also more dangerous to buy from than at any point in its history. The same year that demand exploded, the federal enforcement apparatus turned from warning letters to warehouse raids to criminal prosecutions, and independent laboratories confirmed that roughly one in three products in these categories is mislabeled, off-spec, or contaminated when it arrives at all. This is the central tension of the vertical: buyers are flooding in at the exact moment the channel is most rigged against them. The data below is drawn entirely from primary regulatory sources, peer-reviewed studies, government datasets, on-chain analytics, and independent testing labs — each cited inline. Five headline numbers: $2.6 billion in forfeitures, fines, and restitution was secured by the FDA's Office of Criminal Investigations in fiscal year 2024 alone, alongside 166 arrests and 142 convictions across all FDA-regulated product crimes — the enforcement engine now turning towar…